CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC20A2 (ImmuneEditome ID:6575)

1. Gene summary of enriched editing regions for SLC20A2

check button Gene summary
Gene informationGene symbol

SLC20A2

Gene ID

6575

GeneSynonymsGLVR-2|GLVR2|IBGC1|IBGC2|IBGC3|MLVAR|PIT-2|PIT2|RAM1|Ram-1
GeneCytomap

8p11.21

GeneTypeprotein-coding
GeneDescriptionsodium-dependent phosphate transporter 2|epididymis secretory sperm binding protein|gibbon ape leukemia virus receptor 2|murine leukemia virus, amphotropic, receptor for|murine leukemia virus, amphotropic; receptor|solute carrier family 20 (phosphate transporter), member 2
GeneModificationdate20230517
UniprotIDQ08357;E5RIX1;E5RJW9;E5RGG8;E5RGJ6;E5RGM8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr8:42418190-42418878:-ENST00000342228.6ENSG00000168575.8SLC20A2intronicAluSz,AluYchr8:42418190-42418878:-.alignment
chr8:42418190-42418878:-ENST00000520179.4ENSG00000168575.8SLC20A2intronicAluSz,AluYchr8:42418190-42418878:-.alignment
chr8:42418190-42418878:-ENST00000520262.4ENSG00000168575.8SLC20A2intronicAluSz,AluYchr8:42418190-42418878:-.alignment
chr8:42421189-42421767:-ENST00000342228.6ENSG00000168575.8SLC20A2intronicFLAM_C,L1M5,AluSpchr8:42421189-42421767:-.alignment
chr8:42421189-42421767:-ENST00000520179.4ENSG00000168575.8SLC20A2intronicFLAM_C,L1M5,AluSpchr8:42421189-42421767:-.alignment
chr8:42421189-42421767:-ENST00000520262.4ENSG00000168575.8SLC20A2intronicFLAM_C,L1M5,AluSpchr8:42421189-42421767:-.alignment
chr8:42424405-42425012:-ENST00000342228.6ENSG00000168575.8SLC20A2intronicAluSp,AluSzchr8:42424405-42425012:-.alignment
chr8:42424405-42425012:-ENST00000520179.4ENSG00000168575.8SLC20A2intronicAluSp,AluSzchr8:42424405-42425012:-.alignment
chr8:42424405-42425012:-ENST00000520262.4ENSG00000168575.8SLC20A2intronicAluSp,AluSzchr8:42424405-42425012:-.alignment
chr8:42454159-42455109:-ENST00000518660.4ENSG00000168575.8SLC20A2ncRNA_intronicAluSx,AluJr,MER2,(TA)n,AluY,MIRbchr8:42454159-42455109:-.alignment
chr8:42454159-42455109:-ENST00000522401.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSx,AluJr,MER2,(TA)n,AluY,MIRbchr8:42454159-42455109:-.alignment
chr8:42456575-42457174:-ENST00000518660.4ENSG00000168575.8SLC20A2ncRNA_intronicAluSx3,AluSx1chr8:42456575-42457174:-.alignment
chr8:42456575-42457174:-ENST00000522401.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSx3,AluSx1chr8:42456575-42457174:-.alignment
chr8:42464135-42465498:-ENST00000342228.6ENSG00000168575.8SLC20A2intronic(ACAAA)n,AluSx1,AluJo,AluSx,AluScchr8:42464135-42465498:-.alignment
chr8:42464135-42465498:-ENST00000520179.4ENSG00000168575.8SLC20A2intronic(ACAAA)n,AluSx1,AluJo,AluSx,AluScchr8:42464135-42465498:-.alignment
chr8:42464135-42465498:-ENST00000520262.4ENSG00000168575.8SLC20A2intronic(ACAAA)n,AluSx1,AluJo,AluSx,AluScchr8:42464135-42465498:-.alignment
chr8:42464135-42465498:-ENST00000524211.1ENSG00000168575.8SLC20A2intronic(ACAAA)n,AluSx1,AluJo,AluSx,AluScchr8:42464135-42465498:-.alignment
chr8:42479769-42480873:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_exonicX7A_LINE,AluSz6,AluJochr8:42479769-42480873:-.alignment
chr8:42486308-42489166:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSz,L1MB3,AluSx3,AluJo,AluY,L1M4b,AluSx1chr8:42486308-42489166:-.alignment
chr8:42490436-42491598:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicA-rich,AluSx1,AluSg,AluSzchr8:42490436-42491598:-.alignment
chr8:42505730-42506127:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSx,AluSz6chr8:42505730-42506127:-.alignment
chr8:42509492-42509679:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluJochr8:42509492-42509679:-.alignment
chr8:42522800-42523296:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluJr,AluSx3chr8:42522800-42523296:-.alignment
chr8:42526852-42529194:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSg,AluJo,L1MC3,AluJr,AluY,AluSp,L1ME4a,MIR,(TAT)nchr8:42526852-42529194:-.alignment
chr8:42530743-42532167:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSx1,L2c,AluSc8chr8:42530743-42532167:-.alignment
chr8:42533310-42534271:-ENST00000524237.1ENSG00000168575.8SLC20A2ncRNA_intronicAluSg,AluSx,AluSz6chr8:42533310-42534271:-.alignment


Top

2. Tumor-specific enriched editing regions for SLC20A2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr8:42530743-42532167:-BRCAEER8.1995e-03image
ENSG00000168575.8,SLC20A2BRCAEAG4.4478e-02image
chr8:42530743-42532167:-COADEER7.9491e-03image
chr8:42530743-42532167:-KIRCEER1.1154e-02image
chr8:42533310-42534271:-KIRCEER2.8539e-02image
ENSG00000168575.8,SLC20A2KIRCEAG3.0041e-02image
chr8:42533310-42534271:-KIRPEER7.7240e-03image
ENSG00000168575.8,SLC20A2KIRPEAG1.5129e-03image
chr8:42533310-42534271:-LUSCEER1.2034e-02image
ENSG00000168575.8,SLC20A2LUSCEAG2.5210e-02image
chr8:42530743-42532167:-THCAEER7.6505e-21image
chr8:42533310-42534271:-THCAEER2.0680e-14image
ENSG00000168575.8,SLC20A2THCAEAG1.6261e-15image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr8:42533310-42534271:-ACCPathEER4.6843e-022.7354e-02-0.3290image
chr8:42533310-42534271:-DLBCCliEER9.2010e-032.2331e-020.4549image
chr8:42530743-42532167:-KIRCPathEER1.1819e-021.1270e-030.1605image
chr8:42533310-42534271:-STADPathEER4.5749e-021.3431e-020.1346image
chr8:42530743-42532167:-THCAPathEER2.5722e-041.4795e-050.1941image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr8:42530743-42532167:-THCAEER2.4299e-034.0447e-021.8534e+05image

Top

3. Enriched editing regions and immune related genes for SLC20A2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:42530743-42532167:-GBMEERENSG00000140067,FAM181A0.33464.3538e-033.5874e-070.4103imageNNNANK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr8:42530743-42532167:-KICHEERENSG00000107521,HPS10.60493.2341e-022.4643e-040.4876imageNNHPS1MonocytesGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr8:42530743-42532167:-THCAEERENSG00000183955,SETD8-0.48551.2971e-267.6780e-21-0.4050imageNNNAMonocytesGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr8:42530743-42532167:-THCAEERENSG00000129295,LRRC6-0.46712.3613e-247.7935e-22-0.4144imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:42530743-42532167:-THCAEERENSG00000135951,TSGA10-0.46635.1029e-243.1350e-21-0.4087imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:42530743-42532167:-THCAEERENSG00000232470,RP11-313D6.3-0.43003.4068e-207.9969e-21-0.4048imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:42530743-42532167:-THCAEERENSG00000124160,NCOA5-0.42758.5308e-207.2763e-22-0.4146imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:42530743-42532167:-THCAEERENSG00000110066,SUV420H1-0.42141.1107e-198.9085e-22-0.4138imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_COAGULATION
chr8:42530743-42532167:-THCAEERENSG00000136527,TRA2B-0.40505.0088e-181.4710e-20-0.4022imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:42530743-42532167:-THCAEERENSG00000115414,FN10.38801.1976e-161.3212e-230.4304imageNNFN1Dendritic_cells_restingGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr8:42533310-42534271:-STADEERENSG00000109971,HSPA80.32374.3853e-073.7894e-160.4153imageNNHSPA8T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr8:42533310-42534271:-STADEERENSG00000213189,BTF3L4P20.27952.8058e-051.4838e-150.4075imageNNNAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:42533310-42534271:-STADEERENSG00000248626,GAPDHP400.22301.3793e-032.7555e-150.4039imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:42533310-42534271:-STADEERENSG00000250982,RP11-159J3.10.18591.0659e-021.1840e-180.4460imageNNNAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:42533310-42534271:-STADEERENSG00000239830,RPS4XP220.16292.5336e-024.5769e-150.4010imageNNNAEosinophilsGSVA_HALLMARK_PROTEIN_SECRETION
chr8:42533310-42534271:-READEERENSG00000146556,WASH2P-0.46923.9364e-024.2407e-05-0.4219imageNNNANK_cells_activatedGSVA_HALLMARK_ANDROGEN_RESPONSE
chr8:42533310-42534271:-THYMEERENSG00000100603,SNW10.44562.4800e-047.9103e-060.4343imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr8:42533310-42534271:-THYMEERENSG00000186462,NAP1L20.41408.8703e-042.2396e-050.4142imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr8:42533310-42534271:-THYMEERENSG00000168826,ZBTB490.39272.1157e-031.9590e-050.4168imageNNNAMast_cells_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr8:42533310-42534271:-THYMEERENSG00000143258,USP210.36424.1580e-034.3283e-050.4008imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_PEROXISOME

More results



Top

4. Enriched editing regions and immune related splicing for SLC20A2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:42530743-42532167:-
COADEERMEXENSG00000102882.7chr1630116950:30117003:30117669:30117700:30117705:30117784:30118098:30118163-0.37581.1700e-051.5799e-09-0.4104imageNNMAPK3Macrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2
chr8:42530743-42532167:-
COADEERIRENSG00000177106.10chr11721564:722252:722400:722500-0.17161.0855e-022.9686e-10-0.4347imageNNNANK_cells_restingGSVA_HALLMARK_GLYCOLYSIS
chr8:42530743-42532167:-
GBMEERIRENSG00000125459.10chr1155610619:155611291:155611739:155611827-0.27281.3659e-029.4928e-07-0.4351imageNNNAMast_cells_restingGSVA_HALLMARK_SPERMATOGENESIS
chr8:42533310-42534271:-
GBMEERIRENSG00000072182.8chr2219537631:219537736:219537932:219538772-0.35787.0548e-042.2543e-06-0.4179imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ADIPOGENESIS
ENSG00000168575.8,SLC20A2
GBMEAGIRENSG00000102054.13chrX16852045:16852122:16852415:16852517-0.30346.8840e-033.5853e-06-0.4040imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME
chr8:42533310-42534271:-
GBMEERIRENSG00000117616.13chr125243549:25243633:25244453:25244498-0.39191.2313e-034.1608e-08-0.4321imageNNNAMacrophages_M0GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr8:42533310-42534271:-
GBMEERIRENSG00000117480.11chr146409100:46410497:46410813:46410854-0.32962.0028e-038.7168e-06-0.4064imageNNNAMacrophages_M0GSVA_HALLMARK_ADIPOGENESIS
ENSG00000168575.8,SLC20A2
GBMEAGIRENSG00000197948.6chr5141646086:141646191:141646602:141646722-0.33171.3262e-031.0020e-06-0.4308imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;NONO;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184FCHSD1T_cells_CD8GSVA_HALLMARK_PEROXISOME
chr8:42533310-42534271:-
OVEERIRENSG00000120963.7chr8101202332:101202447:101204649:101204693-0.26447.9229e-059.1310e-11-0.4347imageNNNAMacrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr8:42530743-42532167:-
OVEERIRENSG00000131981.11chr1455137368:55137694:55138044:55138368-0.30972.9952e-062.1406e-11-0.4361imageNNLGALS3Macrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

5. Enriched editing regions and immune infiltration for SLC20A2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr8:42533310-42534271:-ACCEERT_cells_CD4_memory_activated4.9845e-02-0.2909image
ENSG00000168575.8,SLC20A2ACCEAGT_cells_CD4_memory_resting1.8160e-020.2992image
chr8:42530743-42532167:-BLCAEERT_cells_regulatory_(Tregs)1.2784e-03-0.1864image
chr8:42533310-42534271:-BLCAEERT_cells_CD82.7248e-04-0.2050image
ENSG00000168575.8,SLC20A2BLCAEAGT_cells_CD81.1168e-03-0.1743image
chr8:42530743-42532167:-BRCAEERMacrophages_M14.2774e-040.1155image
chr8:42533310-42534271:-BRCAEERT_cells_CD4_memory_activated8.5685e-030.0855image
ENSG00000168575.8,SLC20A2BRCAEAGT_cells_CD4_memory_activated8.4748e-030.0828image
chr8:42530743-42532167:-CESCEEREosinophils6.4500e-03-0.1861image
chr8:42533310-42534271:-CESCEERMast_cells_resting1.8497e-030.2152image
chr8:42530743-42532167:-COADEERNK_cells_resting8.4003e-030.1793image
chr8:42530743-42532167:-DLBCEERDendritic_cells_activated9.4110e-030.5652image
chr8:42533310-42534271:-DLBCEERT_cells_CD84.8739e-020.3629image
ENSG00000168575.8,SLC20A2DLBCEAGT_cells_CD81.5713e-020.4111image
chr8:42464135-42465498:-ESCAEERMast_cells_resting5.7081e-03-0.3142image
chr8:42522800-42523296:-ESCAEERDendritic_cells_resting2.5812e-020.3151image
chr8:42526852-42529194:-ESCAEERT_cells_CD4_memory_resting3.5162e-02-0.2796image
chr8:42530743-42532167:-ESCAEERT_cells_CD4_memory_resting1.1125e-03-0.2555image
chr8:42533310-42534271:-ESCAEERT_cells_regulatory_(Tregs)1.1352e-02-0.1997image
ENSG00000168575.8,SLC20A2ESCAEAGT_cells_regulatory_(Tregs)1.2522e-02-0.1970image
chr8:42530743-42532167:-GBMEERMonocytes2.1533e-040.3047image
chr8:42533310-42534271:-GBMEERT_cells_follicular_helper9.3079e-03-0.2110image
ENSG00000168575.8,SLC20A2GBMEAGT_cells_follicular_helper3.5519e-03-0.2306image
chr8:42530743-42532167:-HNSCEERNeutrophils1.8537e-020.1516image
chr8:42533310-42534271:-HNSCEERNeutrophils7.7381e-030.1515image
ENSG00000168575.8,SLC20A2HNSCEAGNeutrophils1.2739e-020.1346image
chr8:42530743-42532167:-KICHEERMonocytes1.3254e-040.5054image
chr8:42533310-42534271:-KICHEERMonocytes2.7342e-030.4231image
ENSG00000168575.8,SLC20A2KICHEAGMonocytes5.9790e-030.3598image
chr8:42530743-42532167:-KIRCEERT_cells_gamma_delta4.0953e-030.1672image
chr8:42533310-42534271:-KIRCEERDendritic_cells_activated4.6289e-030.1572image
ENSG00000168575.8,SLC20A2KIRCEAGDendritic_cells_activated1.0871e-030.1744image
chr8:42533310-42534271:-KIRPEEREosinophils1.5890e-020.1703image
chr8:42526852-42529194:-LAMLEERMacrophages_M04.7992e-030.2745image
chr8:42530743-42532167:-LGGEERNeutrophils1.2108e-02-0.1114image
chr8:42533310-42534271:-LGGEEREosinophils7.7614e-050.1744image
ENSG00000168575.8,SLC20A2LGGEAGEosinophils2.6302e-090.2561image
chr8:42533310-42534271:-LIHCEERNK_cells_resting2.7162e-020.1747image
ENSG00000168575.8,SLC20A2LIHCEAGNK_cells_activated3.2324e-02-0.1533image
chr8:42530743-42532167:-LUADEERB_cells_naive4.3964e-02-0.1093image
chr8:42533310-42534271:-LUADEERT_cells_regulatory_(Tregs)5.8171e-03-0.1433image
chr8:42418190-42418878:-LUSCEERNeutrophils3.9573e-020.3013image
chr8:42533310-42534271:-LUSCEERDendritic_cells_resting7.4328e-030.1297image
ENSG00000168575.8,SLC20A2LUSCEAGDendritic_cells_resting1.8831e-030.1465image
chr8:42530743-42532167:-MESOEERT_cells_CD86.6328e-030.3791image
chr8:42533310-42534271:-MESOEERNeutrophils1.1913e-020.3254image
ENSG00000168575.8,SLC20A2MESOEAGNeutrophils1.8080e-030.3640image
chr8:42464135-42465498:-OVEERT_cells_CD83.7371e-020.2841image
chr8:42486308-42489166:-OVEERMast_cells_activated3.1101e-030.4406image
chr8:42530743-42532167:-OVEERT_cells_CD82.2060e-020.1373image
chr8:42533310-42534271:-OVEERT_cells_CD82.2787e-020.1365image
ENSG00000168575.8,SLC20A2OVEAGT_cells_CD88.3884e-030.1556image
chr8:42530743-42532167:-PAADEERMacrophages_M02.9037e-030.2526image
ENSG00000168575.8,SLC20A2PAADEAGT_cells_CD4_naive1.8904e-020.1826image
chr8:42530743-42532167:-PCPGEERMacrophages_M12.1542e-020.1851image
chr8:42533310-42534271:-PCPGEERT_cells_regulatory_(Tregs)2.6411e-03-0.2471image
ENSG00000168575.8,SLC20A2PCPGEAGT_cells_regulatory_(Tregs)4.4816e-02-0.1532image
chr8:42530743-42532167:-PRADEERMast_cells_activated2.4310e-02-0.1165image
chr8:42533310-42534271:-READEERNeutrophils4.4591e-030.3004image
ENSG00000168575.8,SLC20A2READEAGNeutrophils1.5685e-040.3841image
chr8:42530743-42532167:-SARCEERT_cells_CD89.1787e-030.1798image
chr8:42533310-42534271:-SARCEERMacrophages_M13.2672e-020.1485image
ENSG00000168575.8,SLC20A2SARCEAGMacrophages_M13.7460e-030.1900image
chr8:42530743-42532167:-SKCMEERT_cells_CD89.1574e-100.3067image
chr8:42533310-42534271:-SKCMEERMonocytes2.0402e-020.1161image
ENSG00000168575.8,SLC20A2SKCMEAGT_cells_CD86.5573e-030.1312image
chr8:42522800-42523296:-STADEERT_cells_CD4_memory_activated9.5672e-030.3144image
chr8:42530743-42532167:-STADEEREosinophils5.9461e-040.1842image
chr8:42533310-42534271:-STADEERT_cells_CD4_memory_activated7.1297e-070.2602image
ENSG00000168575.8,SLC20A2STADEAGNK_cells_resting1.3706e-050.2258image
chr8:42533310-42534271:-TGCTEERMast_cells_resting5.0511e-030.2513image
ENSG00000168575.8,SLC20A2TGCTEAGT_cells_CD4_naive9.1775e-040.2821image
chr8:42530743-42532167:-THCAEERT_cells_regulatory_(Tregs)1.9669e-070.2319image
chr8:42533310-42534271:-THCAEERNK_cells_activated4.2440e-03-0.1315image
ENSG00000168575.8,SLC20A2THCAEAGT_cells_CD81.0087e-03-0.1468image
chr8:42533310-42534271:-THYMEERT_cells_CD4_memory_resting1.2050e-030.3224image
ENSG00000168575.8,SLC20A2THYMEAGMacrophages_M15.1297e-030.2593image
ENSG00000168575.8,SLC20A2UCSEAGNK_cells_resting8.2005e-050.5016image
chr8:42533310-42534271:-UVMEERT_cells_CD85.5308e-03-0.3830image
ENSG00000168575.8,SLC20A2UVMEAGT_cells_CD88.2276e-03-0.3529image


Top

6. Enriched editing regions and immune gene sets for SLC20A2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr8:42530743-42532167:-BRCAEER1.9492e-02image7.8355e-030.0873image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr8:42530743-42532167:-BLCAEER2.4013e-040.21194.0930e-020.11895.9221e-050.23124.0965e-070.2893image
ENSG00000168575.8,SLC20A2STADEAG1.5303e-040.19721.6525e-020.12568.0201e-030.13881.5950e-050.2241image
chr8:42533310-42534271:-STADEER5.4655e-060.23931.3884e-030.16951.7201e-030.16633.6620e-050.2178image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr8:42533310-42534271:-ACCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.9120e-030.4456image
chr8:42530743-42532167:-ACCGSVA_HALLMARK_G2M_CHECKPOINTEER1.4771e-02-0.3242image
ENSG00000168575.8,SLC20A2ACCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.6115e-030.3552image
chr8:42530743-42532167:-BLCAGSVA_HALLMARK_COMPLEMENTEER4.5821e-100.3521image
ENSG00000168575.8,SLC20A2BLCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.0398e-030.1753image
chr8:42533310-42534271:-BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEER3.7063e-040.2006image
chr8:42530743-42532167:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3970e-120.2261image
chr8:42533310-42534271:-BRCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.9078e-060.1481image
ENSG00000168575.8,SLC20A2BRCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.1519e-080.1784image
chr8:42530743-42532167:-CESCGSVA_HALLMARK_COMPLEMENTEER9.5786e-060.2981image
ENSG00000168575.8,SLC20A2CESCGSVA_HALLMARK_HEME_METABOLISMEAG1.3526e-020.1542image
chr8:42533310-42534271:-CESCGSVA_HALLMARK_DNA_REPAIREER2.0731e-02-0.1607image
chr8:42533310-42534271:-CHOLGSVA_HALLMARK_MTORC1_SIGNALINGEER1.3389e-030.5854image
ENSG00000168575.8,SLC20A2CHOLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.4158e-03-0.5095image
chr8:42530743-42532167:-CHOLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.7030e-020.4605image
ENSG00000168575.8,SLC20A2COADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.9445e-050.2499image
chr8:42533310-42534271:-COADGSVA_HALLMARK_P53_PATHWAYEER8.7897e-040.2203image
chr8:42530743-42532167:-COADGSVA_HALLMARK_ANDROGEN_RESPONSEEER8.2800e-030.1797image
chr8:42533310-42534271:-DLBCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.7447e-030.4702image
ENSG00000168575.8,SLC20A2DLBCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.0778e-020.3950image
chr8:42486308-42489166:-ESCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER2.2578e-020.3691image
chr8:42530743-42532167:-ESCAGSVA_HALLMARK_HYPOXIAEER9.3511e-060.3424image
chr8:42533310-42534271:-ESCAGSVA_HALLMARK_P53_PATHWAYEER3.6731e-060.3566image
ENSG00000168575.8,SLC20A2ESCAGSVA_HALLMARK_P53_PATHWAYEAG1.6303e-060.3685image
chr8:42418190-42418878:-ESCAGSVA_HALLMARK_P53_PATHWAYEER2.6684e-020.4261image
chr8:42530743-42532167:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.8750e-040.3075image
ENSG00000168575.8,SLC20A2GBMGSVA_HALLMARK_PEROXISOMEEAG3.8628e-040.2789image
chr8:42533310-42534271:-GBMGSVA_HALLMARK_ADIPOGENESISEER2.8894e-040.2910image
ENSG00000168575.8,SLC20A2HNSCGSVA_HALLMARK_HEME_METABOLISMEAG2.7600e-030.1614image
chr8:42530743-42532167:-HNSCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.4234e-020.1577image
chr8:42533310-42534271:-HNSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.1924e-020.1431image
ENSG00000168575.8,SLC20A2KICHGSVA_HALLMARK_HEME_METABOLISMEAG1.0294e-020.3373image
chr8:42530743-42532167:-KICHGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.1531e-02-0.2986image
chr8:42533310-42534271:-KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.1016e-020.3323image
chr8:42530743-42532167:-KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0136e-060.2810image
chr8:42533310-42534271:-KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.3950e-050.2392image
ENSG00000168575.8,SLC20A2KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.3694e-040.2030image
ENSG00000168575.8,SLC20A2KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.2143e-02-0.1508image
chr8:42530743-42532167:-KIRPGSVA_HALLMARK_UV_RESPONSE_UPEER2.0797e-020.1746image
chr8:42533310-42534271:-KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER2.7452e-030.2107image
chr8:42533310-42534271:-LAMLGSVA_HALLMARK_MYC_TARGETS_V2EER1.2353e-02-0.2038image
ENSG00000168575.8,SLC20A2LAMLGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.8866e-020.1916image
chr8:42533310-42534271:-LGGGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.1761e-030.1357image
ENSG00000168575.8,SLC20A2LGGGSVA_HALLMARK_P53_PATHWAYEAG4.0860e-020.0893image
chr8:42530743-42532167:-LGGGSVA_HALLMARK_MYOGENESISEER1.7235e-070.2296image
ENSG00000168575.8,SLC20A2LIHCGSVA_HALLMARK_HEME_METABOLISMEAG1.7429e-020.1701image
chr8:42533310-42534271:-LIHCGSVA_HALLMARK_HEME_METABOLISMEER3.0317e-030.2330image
chr8:42533310-42534271:-LUADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1745e-030.1683image
chr8:42530743-42532167:-LUADGSVA_HALLMARK_HYPOXIAEER6.8227e-070.2655image
ENSG00000168575.8,SLC20A2LUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.0492e-040.1764image
ENSG00000168575.8,SLC20A2LUSCGSVA_HALLMARK_PEROXISOMEEAG2.7743e-020.1040image
chr8:42418190-42418878:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER3.2667e-02-0.3122image
chr8:42533310-42534271:-MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.3115e-020.2954image
chr8:42530743-42532167:-MESOGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3155e-020.3484image
chr8:42486308-42489166:-OVGSVA_HALLMARK_UV_RESPONSE_UPEER4.8092e-020.3032image
chr8:42530743-42532167:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.0277e-090.3462image
chr8:42464135-42465498:-OVGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.1880e-02-0.2779image
chr8:42533310-42534271:-OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.1369e-100.3690image
ENSG00000168575.8,SLC20A2OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.7997e-100.3594image
chr8:42530743-42532167:-PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.0437e-040.3040image
chr8:42530743-42532167:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.3637e-030.2152image
ENSG00000168575.8,SLC20A2PCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG2.7068e-030.2273image
chr8:42533310-42534271:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER1.5801e-020.1994image
chr8:42530743-42532167:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0051e-040.1821image
chr8:42533310-42534271:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.4642e-040.1779image
ENSG00000168575.8,SLC20A2PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.6493e-050.1901image
ENSG00000168575.8,SLC20A2READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG6.6807e-040.3483image
chr8:42533310-42534271:-READGSVA_HALLMARK_MTORC1_SIGNALINGEER2.3132e-040.3829image
chr8:42530743-42532167:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4225e-020.2550image
chr8:42533310-42534271:-SARCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER8.0832e-070.3350image
chr8:42530743-42532167:-SARCGSVA_HALLMARK_COMPLEMENTEER4.7544e-070.3399image
ENSG00000168575.8,SLC20A2SARCGSVA_HALLMARK_APICAL_SURFACEEAG6.5616e-060.2917image
chr8:42530743-42532167:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5283e-090.3028image
chr8:42533310-42534271:-SKCMGSVA_HALLMARK_HYPOXIAEER3.2783e-030.1469image
ENSG00000168575.8,SLC20A2SKCMGSVA_HALLMARK_HYPOXIAEAG2.4180e-050.2026image
chr8:42533310-42534271:-STADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8921e-080.2936image
chr8:42526852-42529194:-STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.0416e-030.3124image
chr8:42530743-42532167:-STADGSVA_HALLMARK_HYPOXIAEER1.3463e-060.2571image
chr8:42522800-42523296:-STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.0195e-020.2832image
ENSG00000168575.8,SLC20A2STADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.0231e-070.2683image
chr8:42464135-42465498:-STADGSVA_HALLMARK_PEROXISOMEEER9.3036e-040.3845image
chr8:42530743-42532167:-TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.8943e-030.2756image
chr8:42533310-42534271:-TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEER4.6632e-030.2535image
ENSG00000168575.8,SLC20A2TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.1747e-030.2764image
ENSG00000168575.8,SLC20A2THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG9.6853e-110.2844image
chr8:42530743-42532167:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.1017e-100.2855image
chr8:42533310-42534271:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER1.3576e-030.1472image
ENSG00000168575.8,SLC20A2THYMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.0533e-030.2545image
chr8:42533310-42534271:-THYMGSVA_HALLMARK_HEME_METABOLISMEER4.7807e-030.2828image
chr8:42530743-42532167:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.8884e-04-0.3582image
ENSG00000168575.8,SLC20A2UCECGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.4715e-050.3178image
chr8:42533310-42534271:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER2.4362e-030.2657image
chr8:42533310-42534271:-UCSGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.6280e-030.4246image
ENSG00000168575.8,SLC20A2UCSGSVA_HALLMARK_GLYCOLYSISEAG5.0729e-030.3695image
chr8:42533310-42534271:-UVMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.0118e-02-0.3570image
chr8:42530743-42532167:-UVMGSVA_HALLMARK_DNA_REPAIREER2.7364e-020.3533image
ENSG00000168575.8,SLC20A2UVMGSVA_HALLMARK_MTORC1_SIGNALINGEAG4.6420e-02-0.2697image


Top

7. Enriched editing regions and drugs for SLC20A2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr8:42533310-42534271:-ACCBortezomibEER1.4184e-020.3593image
ENSG00000168575.8,SLC20A2ACCGW843682XEAG3.7702e-030.3627image
chr8:42530743-42532167:-ACCAMG.706EER1.2723e-020.3310image
ENSG00000168575.8,SLC20A2BLCAAICAREAG4.4281e-03-0.1524image
chr8:42530743-42532167:-BLCACMKEER9.5709e-09-0.3258image
chr8:42533310-42534271:-BLCAGDC.0449EER2.4375e-040.2066image
ENSG00000168575.8,SLC20A2BRCAABT.263EAG3.6677e-030.0915image
chr8:42530743-42532167:-BRCAABT.263EER2.9019e-070.1679image
chr8:42533310-42534271:-BRCAAMG.706EER1.9906e-030.1005image
ENSG00000168575.8,SLC20A2CESCAZD6482EAG1.6831e-03-0.1954image
chr8:42530743-42532167:-CESCBMS.708163EER1.2668e-04-0.2596image
chr8:42533310-42534271:-CESCAZD6482EER7.5362e-04-0.2324image
chr8:42533310-42534271:-CHOLEpothilone.BEER9.5219e-030.4897image
ENSG00000168575.8,SLC20A2CHOLBIBW2992EAG3.6998e-03-0.5058image
chr8:42530743-42532167:-CHOLDasatinibEER4.2024e-020.4272image
chr8:42530743-42532167:-COADBIRB.0796EER1.0086e-030.2227image
chr8:42533310-42534271:-COADGefitinibEER2.8861e-040.2395image
ENSG00000168575.8,SLC20A2COADABT.888EAG2.2564e-030.1931image
chr8:42533310-42534271:-DLBCBAY.61.3606EER2.2397e-02-0.4155image
ENSG00000168575.8,SLC20A2DLBCGDC.0449EAG2.9344e-020.3740image
ENSG00000168575.8,SLC20A2ESCACGP.60474EAG3.0485e-06-0.3594image
chr8:42526852-42529194:-ESCABIRB.0796EER3.8405e-03-0.3770image
chr8:42418190-42418878:-ESCAAZD6244EER2.4811e-02-0.4310image
chr8:42424405-42425012:-ESCAElesclomolEER1.4699e-02-0.4820image
chr8:42522800-42523296:-ESCAGNF.2EER2.3764e-03-0.4203image
chr8:42530743-42532167:-ESCACGP.60474EER2.2283e-08-0.4244image
chr8:42486308-42489166:-ESCACCT018159EER2.7019e-02-0.3587image
chr8:42533310-42534271:-ESCABI.D1870EER3.3377e-07-0.3904image
chr8:42530743-42532167:-GBMBAY.61.3606EER6.1039e-050.3288image
ENSG00000168575.8,SLC20A2GBMBosutinibEAG1.6460e-030.2484image
chr8:42533310-42534271:-GBMBIRB.0796EER6.4499e-040.2746image
ENSG00000168575.8,SLC20A2HNSCBX.795EAG5.3867e-04-0.1862image
chr8:42530743-42532167:-HNSCBAY.61.3606EER7.9542e-040.2147image
chr8:42533310-42534271:-HNSCBX.795EER1.1084e-03-0.1850image
chr8:42533310-42534271:-KICHBMS.754807EER2.4548e-04-0.5057image
ENSG00000168575.8,SLC20A2KICHBMS.754807EAG6.5369e-04-0.4381image
chr8:42530743-42532167:-KICHErlotinibEER8.5106e-03-0.3612image
ENSG00000168575.8,SLC20A2KIRCKU.55933EAG1.8259e-030.1668image
chr8:42530743-42532167:-KIRCCI.1040EER6.9346e-05-0.2303image
chr8:42533310-42534271:-KIRCGW.441756EER3.8586e-07-0.2779image
ENSG00000168575.8,SLC20A2KIRPA.770041EAG3.5496e-040.2340image
chr8:42533310-42534271:-KIRPAZ628EER5.4933e-040.2434image
chr8:42530743-42532167:-KIRPAG.014699EER3.0967e-030.2224image
ENSG00000168575.8,SLC20A2LAMLA.443654EAG5.8867e-030.2239image
chr8:42533310-42534271:-LAMLA.443654EER4.7831e-030.2292image
chr8:42533310-42534271:-LGGKIN001.135EER5.8723e-05-0.1773image
ENSG00000168575.8,SLC20A2LGGKIN001.135EAG4.6993e-04-0.1521image
chr8:42530743-42532167:-LGGBAY.61.3606EER7.6605e-090.2530image
ENSG00000168575.8,SLC20A2LIHCCHIR.99021EAG1.2623e-03-0.2482image
chr8:42533310-42534271:-LIHCCHIR.99021EER5.8483e-03-0.2343image
chr8:42533310-42534271:-LUADBleomycinEER8.2622e-03-0.1373image
ENSG00000168575.8,SLC20A2LUADBexaroteneEAG1.5660e-03-0.1548image
chr8:42530743-42532167:-LUADA.770041EER1.3343e-02-0.1341image
chr8:42533310-42534271:-LUSCJNK.9LEER2.0213e-02-0.1126image
chr8:42418190-42418878:-LUSCImatinibEER3.0566e-030.4230image
ENSG00000168575.8,SLC20A2LUSCJNK.9LEAG4.7314e-02-0.0938image
chr8:42530743-42532167:-MESOGefitinibEER1.9963e-02-0.3282image
ENSG00000168575.8,SLC20A2MESOGW843682XEAG3.1460e-020.2556image
ENSG00000168575.8,SLC20A2OVAG.014699EAG1.6419e-050.2518image
chr8:42530743-42532167:-OVMG.132EER4.6940e-08-0.3209image
chr8:42464135-42465498:-OVAZD.2281EER3.4173e-02-0.2888image
chr8:42486308-42489166:-OVAICAREER2.7917e-020.3354image
chr8:42533310-42534271:-OVAZD6244EER8.1857e-05-0.2340image
ENSG00000168575.8,SLC20A2PAADBMS.536924EAG1.8021e-020.1856image
chr8:42530743-42532167:-PAADAZD6482EER2.2734e-020.1960image
chr8:42533310-42534271:-PAADCyclopamineEER3.0175e-020.1833image
chr8:42530743-42532167:-PCPGGemcitabineEER3.1751e-030.2363image
ENSG00000168575.8,SLC20A2PCPGCamptothecinEAG1.9321e-020.1782image
chr8:42530743-42532167:-PRADEpothilone.BEER3.3137e-030.1515image
ENSG00000168575.8,SLC20A2PRADAZD6482EAG1.1258e-03-0.1544image
chr8:42533310-42534271:-PRADBMS.509744EER9.6326e-030.1316image
chr8:42530743-42532167:-READGemcitabineEER4.7597e-02-0.2250image
chr8:42533310-42534271:-READDocetaxelEER1.3178e-02-0.2633image
ENSG00000168575.8,SLC20A2READDocetaxelEAG2.8509e-03-0.3077image
chr8:42530743-42532167:-SARCAP.24534EER1.0753e-08-0.3827image
chr8:42533310-42534271:-SARCAP.24534EER8.3630e-04-0.2304image
ENSG00000168575.8,SLC20A2SARCAP.24534EAG9.7192e-07-0.3156image
chr8:42530743-42532167:-SKCMAZD6244EER9.0894e-05-0.1989image
chr8:42533310-42534271:-SKCMCGP.082996EER1.7239e-04-0.1870image
ENSG00000168575.8,SLC20A2SKCMCGP.082996EAG8.3497e-06-0.2135image
chr8:42533310-42534271:-STADAZD8055EER4.5583e-04-0.1856image
chr8:42526852-42529194:-STADBI.2536EER4.3618e-030.3011image
ENSG00000168575.8,SLC20A2STADAZD8055EAG4.7128e-05-0.2116image
chr8:42522800-42523296:-STADCI.1040EER3.1274e-02-0.2634image
chr8:42530743-42532167:-STADAZ628EER4.1818e-06-0.2452image
chr8:42464135-42465498:-STADAG.014699EER2.0738e-030.3595image
ENSG00000168575.8,SLC20A2TGCTCMKEAG3.3838e-02-0.1828image
chr8:42533310-42534271:-TGCTEmbelinEER3.9892e-02-0.1856image
chr8:42530743-42532167:-TGCTAS601245EER5.1182e-030.2676image
ENSG00000168575.8,SLC20A2THCACEP.701EAG2.5626e-090.2629image
chr8:42530743-42532167:-THCACI.1040EER5.9795e-16-0.3538image
chr8:42533310-42534271:-THCABMS.754807EER4.0651e-040.1623image
chr8:42530743-42532167:-THYMBAY.61.3606EER1.9279e-030.3007image
ENSG00000168575.8,SLC20A2THYMAxitinibEAG5.3832e-040.3178image
chr8:42533310-42534271:-THYMA.770041EER1.1418e-030.3239image
ENSG00000168575.8,SLC20A2UCECCHIR.99021EAG1.3518e-02-0.1955image
chr8:42533310-42534271:-UCECImatinibEER2.0102e-02-0.2053image
ENSG00000168575.8,SLC20A2UCSMetforminEAG3.5252e-03-0.3835image
chr8:42533310-42534271:-UCSEHT.1864EER1.5715e-030.4440image
chr8:42530743-42532167:-UVMJNJ.26854165EER4.4440e-02-0.3236image
chr8:42533310-42534271:-UVMFH535EER9.0325e-03-0.3621image
ENSG00000168575.8,SLC20A2UVMCHIR.99021EAG8.9397e-03-0.3494image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType